Toll-like receptor-7 ligand imiquimod induces type I interferon and antimicrobial peptides to ameliorate dextran sodium sulfate-induced acute colitis

Inflammatory Bowel Diseases

Volumn 18, Issue 5, 2012, Pages 955-967

  Sainathan, Satheesh K ^a   Bishnupuri, Kumar S ^a   Aden, Konrad ^b   Luo, Qizhi ^a   Houchen, Courtney W ^c   Anant, Shrikant ^d   Dieckgraefe, Brian K ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY OF OKLAHOMA   (United States)

^d UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Epithelial cells; Inflammatory bowel diseases; Innate immunity; Mucosa

Indexed keywords

ALPHA2 INTERFERON; BETA INTERFERON; DEXTRAN SULFATE; GENTAMICIN; IMIQUIMOD; INTERFERON; MESSENGER RNA; MYELOPEROXIDASE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TOLL LIKE RECEPTOR 7;

ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; COLITIS; COLON MUCOSA; CONTROLLED STUDY; DENDRITIC CELL; DISEASE ACTIVITY; DISEASE PREDISPOSITION; DRUG EFFECT; ENZYME ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; INTESTINE EPITHELIUM CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALMONELLA TYPHIMURIUM; SPLEEN;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; AMINOQUINOLINES; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL MARKERS; COLITIS; CYTOKINES; DEXTRAN SULFATE; FEMALE; GASTROINTESTINAL TRACT; GENE EXPRESSION PROFILING; HUMANS; INTERFERON INDUCERS; INTERFERON TYPE I; MICE; MICE, INBRED BALB C; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEROXIDASE; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SALMONELLA INFECTIONS; SALMONELLA TYPHIMURIUM; SURVIVAL RATE; TOLL-LIKE RECEPTOR 7;

EID: 84859790202     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21867     Document Type: Article

References (44)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-429. (Pubitemid 34851835)
2. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006;12(Suppl 1):S3-9. (Pubitemid 43068428)
3. Present DH. 6-Mercaptopurine and other immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis. Gastroenterol Clin North Am. 1989;18:57-71. (Pubitemid 19077648)
4. Blumberg RS. Inflammation in the intestinal tract: pathogenesis and treatment. Dig Dis. 2009;27:455-464.
5. Obermeier F, Dunger N, Strauch UG, et al. CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation. Gastroenterology. 2005;129:913-927. (Pubitemid 41242684)
6. Obermeier F, Hofmann C, Falk W. Inflammatory bowel diseases: when natural friends turn into enemies-the importance of CpG motifs of bacterial DNA in intestinal homeostasis and chronic intestinal inflammation. Int J Inflamm. 2010:641910.
7. Katakura K, Lee J, Rachmilewitz D, et al. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest. 2005;115:695-702. (Pubitemid 40322244)
8. Bottrel RL, Yang YL, Levy DE, et al. The immune response modifier imiquimod requires STAT-1 for induction of interferon, interferon-stimulated genes, and interleukin-6. Antimicrob Agents Chemother. 1999;43:856-861. (Pubitemid 29165749)
9. Lore K, Betts MR, Brenchley JM, et al. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J Immunol. 2003;171:4320-4328. (Pubitemid 37238711)
10. Diebold SS, Kaisho T, Hemmi H, et al. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004;303:1529-1531. (Pubitemid 38314425)
11. Prins RM, Craft N, Bruhn KW, et al. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol. 2006;176:157-164. (Pubitemid 43023259)
12. Palamara F, Meindl S, Holcmann M, et al. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol. 2004;173:3051-3061. (Pubitemid 39142011)
13. Wolf IH, Cerroni L, Kodama K, et al. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol. 2005;141:510-514. (Pubitemid 40547412)
14. Gupta AK, Cherman AM, Tyring SK. Viral and nonviral uses of imiquimod: a review. J Cutan Med Surg. 2004;8:338-352. (Pubitemid 41542423)
15. Gupta AK, Browne M, Bluhm R. Imiquimod: a review. J Cutan Med Surg. 2002;6:554-560. (Pubitemid 36091502)
16. Edwards AD, Diebold SS, Slack EM, et al. Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. Eur J Immunol. 2003;33:827-833. (Pubitemid 36546669)
17. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3:196-200. (Pubitemid 34141451)
18. Doxsee CL, Riter TR, Reiter MJ, et al. The immune response modifier and Toll-like receptor 7 agonist S-27609 selectively induces IL-12 and TNF-alpha production in CD11c+CD11b+CD8- dendritic cells. J Immunol. 2003;171:1156-1163. (Pubitemid 36900043)
19. Miller RL, Gerster JF, Owens ML, et al. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol. 1999;21:1-14. (Pubitemid 29097684)
20. Loher F, Schmall K, Freytag P, et al. The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice. J Pharmacol Exp Ther. 2003;305:549-556. (Pubitemid 36459169)
21. Gonzalez-Rey E, Delgado M. Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide. Gastroenterology. 2006;131:1799-1811. (Pubitemid 44958527)
22. Sainathan SK, Tu L, Bishnupuri KS, et al. PEGylated murine Granulocyte-macrophage colony-stimulating factor: production, purification, and characterization. Protein Expr Purif. 2005;44:94-103. (Pubitemid 41565557)
23. Savage P, Horton V, Moore J, et al. A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. Br J Cancer. 1996;74:1482-1486. (Pubitemid 26370744)
24. Uehara A, Fujimoto Y, Fukase K, et al. Various human epithelial cells express functional Toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokines. Mol Immunol. 2007;44:3100-3111. (Pubitemid 46610510)
25. Figueroa C, Peralta A, Herrera L, et al. NOD2/CARD15 and Toll-like 4 receptor gene polymorphism in Chilean patients with inflammatory bowel disease. Eur Cytokine Netw. 2006;17:125-130.
26. Franchimont D, Vermeire S, El Housni H, et al. Deficient host-bacteria interactions in inflammatory bowel disease? The Toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut. 2004;53:987-992. (Pubitemid 38824157)
27. van Heel DA, Ghosh S, Hunt KA, et al. Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn's disease. Gut. 2005;54:1553-1557. (Pubitemid 41531770)
28. Korzenik JR, Dieckgraefe BK, Valentine JF, et al. Sargramostim for active Crohn's disease. N Engl J Med. 2005;352:2193-2201. (Pubitemid 40727086)
29. Sainathan SK, Hanna EM, Gong Q, et al. Granulocyte macrophage colony-stimulating factor ameliorates DSS-induced experimental colitis. Inflamm Bowel Dis. 2008;14:88-99. (Pubitemid 351196873)
30. Reiter MJ, Testerman TL, Miller RL, et al. Cytokine induction in mice by the immunomodulator imiquimod. J Leukoc Biol. 1994;55:234-240. (Pubitemid 24066348)
31. Fitzgerald-Bocarsly P, Dai J, Singh S. Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev. 2008;19:3-19.
32. Rachmilewitz D, Karmeli F, Takabayashi K, et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology. 2002;122:1428-1441. (Pubitemid 34465184)
33. Rachmilewitz D, Katakura K, Karmeli F, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology. 2004;126:520-528. (Pubitemid 38182309)
34. Obermeier F, Dunger N, Strauch UG, et al. Contrasting activity of cytosin-guanosin dinucleotide oligonucleotides in mice with experimental colitis. Clin Exp Immunol. 2003;134:217-224. (Pubitemid 37372272)
35. Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet. 1997;349:521-524. (Pubitemid 27092789)
36. Ferretti M, Casini-Raggi V, Pizarro TT, et al. Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest. 1994;94:449-453. (Pubitemid 24218125)
37. Falasca K, Ucciferri C, Dalessandro M, et al. Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann Clin Lab Sci. 2006;36:144-150.
38. Farinati F, Cardin R, Bortolami M, et al. Oxidative damage, pro-inflammatory cytokines, TGF-alpha and c-myc in chronic HCVrelated hepatitis and cirrhosis. World J Gastroenterol. 2006;12: 2065-2069.
39. Thomas A, Laxton C, Rodman J, et al. Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection. Antimicrob Agents Chemother. 2007;51:2969-2978. (Pubitemid 47206238)
40. Goldstein D, Hertzog P, Tomkinson E, et al. Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. J Infect Dis. 1998;178:858-861. (Pubitemid 28397238)
41. Wu CC, Hayashi T, Takabayashi K, et al. Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proc Natl Acad Sci U S A. 2007;104:3990-3995. (Pubitemid 47181566)
42. Chan M, Hayashi T, Kuy CS, et al. Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates. Bioconjug Chem. 2009;20:1194-1200.
43. Eckmann L. Defence molecules in intestinal innate immunity against bacterial infections. Curr Opin Gastroenterol. 2005;21:147-151. (Pubitemid 40316195)
44. Steinbrecher KA, Harmel-Laws E, Sitcheran R, et al. Loss of epithelial RelA results in deregulated intestinal proliferative/apoptotic homeostasis and susceptibility to inflammation. J Immunol. 2008;180:2588-2599.